NCT03928938

Follow-up of Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy by Electronic Patient Reported Outcomes-tool

Completed NA Last updated 29 August 2025

What this trial tests

NA trial testing Electronic patient reported outcomes in Cancer in 43 participants. Completed in 31 December 2022.

Timeline

1 June 2017

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Oulu University Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	43
Start date	1 June 2017
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	2 locations across Finland

Drugs / interventions tested

• Electronic patient reported outcomes

Conditions studied

• Cancer — all drugs for Cancer →

Sponsor

Oulu University Hospital

Who can join

18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Electronic patient reported outcome (ePRO) tools have improved survival and quality of life (QoL) of cancer patients receiving chemotherapy, and in the follow-up of lung cancer patients. Current study investigates electronic patient reported outcome tool in the follow-up of cancer patients receiving immune checkpoint inhibitor therapy.

Current study aims to evaluate 1) patient reported symptoms and their severity, 2) Number of triggered alerts by the tool and their correlation to treatment side-effects, cancer progression, other medical events or survival, 3) Correlation between different symptoms and the correlation of symptoms to treatment side-effects, cancer progression, other medical events or survival,4) QoL of patients and correlation of changes in QoL to treatment side-effects, cancer progression, other medical events or survival, 5) Patient compliance, 6) Correlation of baseline laboratory values to treatment side-effects, cancer progression, other medical events or survival.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies.
   Iivanainen S, Ekstrom J, Virtanen H, Kataja VV, et al · · 2021 · cited 30× · PMID 34193140 · DOI 10.1186/s12911-021-01564-0
2. Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study.
   Iivanainen S, Alanko T, Vihinen P, Konkola T, et al · · 2020 · cited 23× · PMID 33112242 · DOI 10.2196/17898